Vir's stock is up 12% after news it will join the S&P SmallCap 600
Shares of Vir Biotechnology Inc. were up 12.8% in premarket trading on Wednesday, the day after it was announced that the stock will join the S&P SmallCap 600 , effective April 4. The company is led by George Scangos, the former CEO of Biogen Inc. ; it has one authorized therapy, the COVID-19 monoclonal antibody, sotrovimab. Vir's stock is down 46.0% so far this year, while the S&P SmallCap 600 has declined 2.9%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.